MapLight Therapeutics(NASDAQ) MPLT

MapLight Therapeutics makes medicines for severe brain disorders. These treatments help people with schizophrenia and autism. The company maps brain circuits to find new therapies.

The Clinical Drug Pipeline

• ML-007C-MA: Combined treatment targeting schizophrenia and psychosis associated with Alzheimer's disease.
• ML-004: Therapy designed to reduce social communication deficits and irritability in autism.
• ML-021: Investigational candidate aimed at treating motor impairments for patients with Parkinson's disease.
• ML-009: Experimental compound for conditions involving hyperactivity and agitation.
• Discovery Platform: Neural circuit mapping tool used to identify and target specific disease-linked brain regions.

Milestones and Capital Moves

• Closed an initial public offering in Oct. 2025 with net proceeds of $261.6 million.
• Secured Fast Track designation from the FDA in Dec. 2025 for its Alzheimer's psychosis candidate.
• Announced positive Phase 2 clinical trial results for its schizophrenia treatment candidate in July 2026.
• Entered a securities purchase agreement for a $150.0 million private placement in Aug. 2026.

How MapLight Maps the Mind

MapLight utilizes a specialized platform to map neural circuits and create medicines for specific brain functions. This approach helps the company develop treatments that aim to be effective while reducing unwanted side effects.

The Costs of Research

• Net loss was $120.9 million for the six months ended June 30, 2026.
• Research and development expenses totaled $107.1 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and investments were $351.3 million as of June 30, 2026.
• General and administrative expenses were $20.9 million for the six months ended June 30, 2026.

Bottom Line

MapLight has evolved from a research startup into a public developer of specific neural circuit therapies. Its progress relies on clinical trial results and successful capital raises to fund ongoing research.